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Abstract
EGFR-type receptor tyrosine kinases achieve a broad spectrum of
cellular responses by utilizing a set of structurally conserved
building blocks. Based on available crystal structures and
biochemical information, significant new insights have emerged
into modes of receptor control, its deregulation in cancer, and the
nuances that differentiate the four human receptors. This review
gives an overview of current models of the control of receptor
activity with a special emphasis on HER2 and HER3.
Introduction
The deregulation of type I receptor tyrosine kinases (RTKs) is
a critical aspect of many cancers. In humans this signaling
system includes four members: epidermal growth factor
receptor (EGFR; ERBB1), human epidermal growth factor
receptor (HER)2/neu (ERBB2), HER3 (ERBB3) and HER4
(ERBB4). This review uses the historical HER2 nomenclature
in light of the fact that a large body of clinically relevant work
has used this identifier, but it should be noted that the Human
genome organization Gene Nomenclature Committee
approved identifier for HER2 is ERBB2.
Among the various cancers, breast cancers stand out in that
not only is over-expression of HER2 a frequent occurrence
(20% to 30%) in these cancers but also therapeutic targeting
of HER2 with humanized antibodies has proven to be a
promising approach to treatment. This over-expression of
HER2 in breast cancers is accompanied by high levels of
constitutively active receptors. Hence, inhibition of this
elevated level of constitutive signaling has been a prime
objective in the design of therapies. However, notwith-
standing the success of therapies targeted against HER2,
specifically the use of trastuzumab (Herceptin; Genentech,
San Francisco, CA, USA), many mechanistic aspects of
signaling by HER2 remain poorly understood. The mode of
action of Herceptin, which targets the extracellular domains
(ECDs) of HER2, is likewise poorly understood and cannot
be explained by simple inhibition of ligand-independent
receptor association events. (See the paper by Nahta and
Esteva [1] for a recent review on the actions of Herceptin.)
This limits knowledge-based improvements in therapy and our
ability to counteract rapidly emerging resistance (reviewed
elsewhere in this series). Part of the problem lies in the fact
that type I RTKs, and the ligand binding-deficient HER2 in
particular, do not act as autonomous units but as a complex
interconnected regulatory system.
Ligand-activated receptor dimers are at the core of signaling
by EGFR-type RTKs, resulting in a network of combinatorial
receptor interactions. The complexity of this network is further
enhanced by a range of ligands with diverse receptor
specificity [2]. Once activated, the receptors can signal
through at least four alternative pathways, specifically the
mitogen-activated protein kinase pathway, phospholipase Cγ,
phosphatidylinositol-3 kinase stimulation of antiapoptotic AKT
kinase signaling, and finally STAT (signal transducer and
activator of transcription) signaling as the most direct route to
transcriptional control [3]. The outcome of signaling can
range from cell proliferation to differentiation and apoptosis.
These alternate routes to signaling are further modulated by
the fact that the complement of signaling partners will not
only differ between cell types but also with respect to
subcellular localization. However, our understanding of
receptor function is largely based on biochemical ensemble
measurements. We know next to nothing about the extent to
which an individual receptor can engage in signaling in these
different pathways simultaneously or sequentially, or whether
these signaling events are mutually exclusive at the level of a
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single receptor. This limitation in our understanding is of
course not unique to HER2 signaling but should be kept in
mind, especially as we attempt to interpret results indicating
signaling complexes that involve large protein scaffolds.
Much of our mechanistic knowledge on RTK signaling is based
on EGFR, which is by far the best studied member in this
family. However, EGFR differs in many key aspects from HER2.
This review emphasizes mechanistic foundations of type I RTK
signaling, derived from structure and function analyses of all
four family members, with an emphasis on HER2.
The basic paradigm of ligand-induced
dimerization and transphosphorylation
All four EGFR-type RTKs share a very conserved structural
framework (Figure 1a), which consists of four ECDs, a single
transmembrane span, a cytoplasmic juxtamembrane linker
region, a tyrosine kinase component, and a carboxyl-terminal
tail. This carboxyl-terminal tail is the main substrate of activation-
dependent tyrosine phosphorylation and subsequent recruit-
ment of adapter proteins, although tyrosine phosphorylation
has also been reported in the kinase domains itself [4,5]. The
basic paradigm for activation control centers on ligand-
induced homo- and hetero-dimerization of receptors, followed
by tyrosine phosphorylation of the cytoplasmic portions of the
receptors in trans. Based on confirmed receptor tyrosine
phosphorylation sites, a recent microarray-based study
determined the ability of such tyrosine phosphorylated-
peptides to recruit SH2 or phosphotyrosine-binding domains
[4]. This study revealed significant differences between the
four RTK family members. Although HER3 exhibited few
changes in its recruitment pattern as a function of peptide
(‘bait’) concentration, significant changes occurred for HER2
suggesting that the complement of adapter proteins recruited
by activated HER2 would qualitatively vary significantly more
as a function of the levels of activated receptors. In addition, a
projection for different receptor pairs showed that the
HER2/HER3 heterodimer outperforms other RTK combina-
tions in terms of the range of recruited adapters and its ability
to carry out efficient recruitment at low to medium concentra-
tions of tyrosine phosphorylated sites. This is consistent with
earlier observations that the HER2/HER3 heterodimer
represents the most potent mitogenic signaling pair [2].
The unique nature of the HER2/HER3 receptor pair in
signaling is also reflected in the basic mode of activation,
Figure 1
Schematic representation of domains, conformations, and sites of interaction in HER2 and HER3. (a) Domain structure of monomeric HER2,
indicating ECDs I to IV with the primary and secondary dimerization loop in the fifth and sixth module of domain II, a single transmembrane span,
the cytoplasmic juxtamembrane segment (* indicates the site of PKC-mediated threonine phosphorylation), the amino- and carboxyl-terminal lobe of
the kinase domain, and the carboxyl-terminal tail carrying most adapter binding sites. The sites targeted by Herceptin (Herc.), calmodulin (CaM),
and Hsp90 are indicated with arrows. (b) Model of HER2-HER3 heterodimer with bound ligand. NRG indicates the EGF-like domain of neuregulin,
bound between domains I and III, and Ig indicates the location of the immunoglobulin-like amino-terminal domain of neuregulins. The receptor dimer
is stabilized by reciprocal interactions between domains II of both receptors. The physical separation of domains IV in the diagram does not
necessarily indicate physical distance but is meant to emphasize that based on experimental data, and in contrast to transmembrane span packing,
domain IV interactions do not contribute significantly to dimer stabilization. The exact nature of interactions by both components (boxed with
dashed lines) is not clear at this point. The indicated interactions of the cytoplasmic kinase domains summarize the recently proposed mode of
allosteric activation based on EGFR structures [38]. (c) HER3 in the closed/locked conformation, stabilized by an intramolecular tether involving
the primary dimerization loop in domain II and its structural equivalent in domain IV. ECD, extracellular domain; EGFR, epidermal growth factor
receptor; HER, human epidermal growth factor receptor; PKC, protein kinase C.Page 3 of 8
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which features a ‘separation of duties’, as compared with the
basic model established by homodimers of EGFR. Although
EGFR and HER4 can form fully functional homodimers,
HER3 has impaired kinase activity [6] and relies on the kinase
activity of its heterodimerization partners for activation [7].
HER2 fails to bind any of the known RTK ligands but
contributes its kinase activity to all possible heterodimers.
Although HER2 itself does not bind any known ligand, it is
believed that many of the molecular details in receptor
interactions, established for homodimers of ligand-bound
EGFR, extend to heterodimers of HER2 with its ligand
binding partners, primarily EGFR and HER3.
The different RTKs exhibit preferential binding to subsets of
ligands, with EGFR binding EGF and related ligands whereas
HER3 and HER4 bind neuregulins (NRGs; also referred to as
heregulins). NRGs are a large family of ligands arising from
alternative splice variants of four NRG genes [8]. NRGs and
EGF-type ligands share an essential and structurally almost
identical EGF-like domain, and are generated by proteolytic
processing of membrane bound precursors. Enhanced
signaling via the HER3/HER2 receptor pair is one of the
routes of resistance encountered in EGFR-targeted
therapies. The inhibition of the ADAM protease-mediated
proteolytic processing of the cell surface precursors of NRGs
has recently been evaluated as a drug target in non-small-cell
lung cancers that showed resistance to the EGFR kinase
inhibitor gefitinib (Iressa; AstraZeneca, Wilmington, DE, USA)
[9]. This study identified NRG processing as a promising
point of therapeutic intervention. In contrast to EGF, where
processing occurs amino- and carboxyl-terminal of the
peptide-size EGF domain, all known mature NRGs retain
additional but diverse domains amino-terminal of the EGF-like
domain that are not required for activation on the basic level
of receptor dimers. However, these additional amino-terminal
domains, or the presence of unrelated domains of
comparable size, are required for efficient receptor
downregulation and signal attenuation [10]. Because this
enhancement in signal attenuation correlates with an
enhanced disruption of previously observed higher order
oligomers of HER3 receptors [11], this may provide a
glimpse into the additional control mechanisms that act upon
RTK receptors on the level of higher order association states,
which arguably is one of the least understood aspects of RTK
signaling at this point.
Insight into the mode of ligand binding and receptor
interaction comes from crystal structures of the ECDs with
and without ligand. Several in-depth reviews of these studies
are available [12,13]. Structurally, all four RTK receptors
contain four ECDs. Domain I (also named L1) is structurally
highly homologous to domain III (L2; each approximately 170
residues), and domain II (C1 or S1) is homologous to domain
IV (C2 or S2; each approximately 140 residues). Ligand
binding occurs on the ‘outside’ of dimers, not the receptor-
dimer interface, and involves interactions with domains I and
III (Figure 1b), both of which have a β helical structure.
However, the relative contribution by domains I and III to
ligand binding differs between receptors, with domain III
being the main contributor for EGF binding to EGFR [14]
whereas domain I is the dominant site of interaction for NRG
binding to HER3 [15,16] and HER4 [17].
In the structure of ligand-free HER2 ECDs, domains I and III
interact with each other in a fashion that would block ligand
access, in part explaining the lack of ligand binding by HER2.
Whether this feature is truly unique to HER2 will remain
unknown until the structures of other family members in their
ligand-free and extended conformations are resolved.
Currently available, ligand-free structures for EGFR and
HER3 demonstrate the receptors to be in a significantly
different and tethered conformation, which is likely to be in
equilibrium with an extended conformation similar to that
observed for HER2. The cysteine-rich domains II and IV also
feature a high degree of structural similarity, especially with
respect to their individual laminin-like modules, which are
arranged in a linear fashion. However, this similarity is
deceiving. When they are individually classified based on the
nature of their disulfide bonding, domains II and IV differ in
the number and subtype of laminin-like modules [12] (shown
as differences in module shape in Figure 1a). More
importantly, the contribution of both domains to receptor
function appears to be very distinct.
The crystal structures of the ECDs of EGFR with bound
ligand outline key aspects of ligand binding and receptor
dimerization [18,19]. However, in both crystal structures
domain IV was either not resolved or had to be removed to
facilitate crystallization. Domain II directly stabilizes the dimer
through interlocking dimerization loops of two interacting
receptors. Those primary dimerization loops protrude from
the fifth module of domain II. This interaction was not
detected in the absence of ligand for soluble constructs
consisting of only domains I to III [20], suggesting that
interactions through this interface are very weak in the
absence of ligand-induced conformational changes because
the ligand itself is not part of the dimer interface. Additional
interactions occur through a smaller loop protruding from the
sixth module of domain II, and those interactions have been
implicated in providing discrimination for the formation of the
correct heterodimers and the enforcement of ligand-induced
conformational changes in the activation process [21].
Although domain IV is structurally similar to domain II,
mutagenesis of domain IV indicates that it does not
contribute significantly to stabilizing dimers [21]. This
observation is consistent with the inability of domain IV to
assume a stable and defined conformation in crystals of
EGFR-ECD dimers.
The ECDs can therefore be divided into two functional units:
domains I to III, containing ligand binding and key dimerization
controls, and a functionally distinct domain IV. This
Available online http://breast-cancer-research.com/content/9/1/202classification resembles the evolutionary related insulin
receptor (IR) as well as the insulin-like growth factor (IGF)1
receptor, despite large differences in the nature of ligands for
both RTK families. Indeed, the degree of structural
conservation between the first three domains of IR and
EGFR-type RTKs is very high [22]. However, domain IV is
absent in IR/IGF1R and is functionally replaced with a
second polypeptide chain (β). The β-chain of IR/IGF1R
establishes covalent links to the α-chain (domains I to III) and
between  β-chains of two receptors, thereby generating a
covalently linked dimer. Given that domain IV is the most
significant point of departure between the otherwise very
homologous IR and EGFR family of RTKs, it will be interesting
to see in the future what this segment contributes to function
because it is likely to serve a purpose in controlled signaling
beyond that of a mere spacer. Because it is domain IV of
HER2 that is the target of Herceptin binding [23], this lack of
understanding of the exact contribution by domain IV also
complicates current efforts to place the activity of Herceptin
on a mechanistic foundation.
Although the mechanistic contribution of domain IV in the
ligand-bound receptor dimer is currently not clear, domain IV
is a critical component in the formation of an intramolecular
tether between the ‘dimerization loop’ in domain II and a
similar loop in domain IV (Figure 1c). This intramolecular
‘tether’ or ‘lock’ was first observed in the crystal structure of
the ECDs of HER3 [24] and subsequently in several
structures of EGFR, and HER4 [25-27]. In contrast, the
ECDs of HER2 represent the only example thus far in which
all four ECDs crystallized as a monomer in an extended
conformation, representing a structure expected to be similar
to that of individual receptors in a receptor dimer. The
dimerization interface in the tethered conformation is not
available for intermolecular interactions, and the ligand
binding pocket between domain I and III is disrupted. This
provided a very attractive and structure-based model for
receptor activation control in which the intramolecular tether
presents a barrier to spontaneous dimerization and activation
[12]. The inability of HER2 to adopt this ‘autoinhibited’
conformation was expected to result in a receptor,
predisposed to uncontrolled dimerization and signaling,
which correlates nicely with the high transforming potential of
HER2 [28]. However, although the inability of HER2 to
assume an autoinhibited conformation may contribute to its
potency, subsequent mutagenesis of the tether in EGFR
[19,29] and HER3 ECDs (evaluated in the context of an
HER3-HER2 chimera) [11] surprisingly showed little impact
of a defective tether on the suppression of basal activation.
For soluble ECDs of EGFR, the release of the tethering
mechanism results in a modest increase in the affinity for EGF
[25], consistent with an increased availability of ligand
binding sites in the extended conformation. Recent modeling
and direct measurements of the impact of the tether on ligand
binding in a cellular setting likewise indicated only a modest
twofold increase in ligand binding affinity [30].
However, the presence of the tether in several crystal
structures of EGFR, HER3, and HER4 strongly suggests that
this conformation is biologically relevant. Interestingly, two
crystal structures (ECDs of EGFR and HER4) were obtained
at pH 5.0 to 5.5 [25,27], a pH range comparable to the
environment of late endosomes. This highlights another
aspect of ligand binding: pH dependency. At endosome pH,
EGFR loses most of its affinity for EGF or transforming
growth factor-α (but not betacellulin), whereas HER3 and
HER4 retain significant ligand binding affinity [16,27].
Surprisingly, the ability of HER3 to bind ligand at low pH is
even further enhanced in the locked/tethered conformation
[16]. This is of interest not only for HER3 but also for HER2,
because the endosome is emerging as a compartment not
only for downregulation and sorting but also for signaling. In
the case of EGFR, signaling can be initiated from endosomes
[31], and the endosomal protein P14 is needed to recruit the
mitogen-activated protein kinase scaffolding protein MP1
[32]. Although HER2 itself is apparently deficient in stable
tether formation, conditions that favor the adaptation of the
tethered conformation by its heterodimerization partners are
expected to shift the equilibrium between HER2 containing
heterodimers and dissociated receptor complexes in favor of
dissociated receptors. This may alter the recruitment of
adapter proteins and influence receptor routing. Hence, the
tethered conformation, whose role on the cell surface is not
yet clear, may potentially play a more prominent role in
modulating receptor actions in endosomal compartments.
Beyond dimerization: additional control
mechanisms within receptor complexes
Whether receptor dimerization is sufficient for activation was
questioned in the past [33], and several studies challenged the
model of purely association driven activation. Although
dimerization of engineered intermolecular disulfides can activate
EGFR [34], similar experiments using HER2 have not resulted in
activated receptors [35], indicating that spatial proximity alone is
not sufficient to ensure efficient phosphorylation. Likewise,
cytoplasmic kinase segments fused to strongly dimerizing
transmembrane spans alone do not result in activation.
Cysteines placed at various positions throughout the membrane
spanning helix of EGFR identify preformed dimers with distinct
interfaces in the active and inactive state, demonstrating
preformed but active receptor dimers and suggesting rotational
transitions in the packing of the transmembrane span upon
activation [36]. In contrast, the loss of the ECDs of HER2 in the
context of its natural transmembrane domains has long been
known to result in constitutive activation [37]. Recent
experiments in which kinase domains were artificially anchored
to a membrane surface likewise resulted in active kinases [38].
The overall picture that appears to emerge from a broad range
of studies suggests that spatial proximity or dimerization is
sufficient for activation when intrinsic control mechanisms have
been disabled through mutation, truncation, or out-of-context
fusion of kinase domains, whereas dimerization alone is not
sufficient when intrinsic control mechanisms are retained.
Breast Cancer Research    Vol 9 No 1 Landgraf
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insufficient for activation, it may also not be the end-point in
receptor association states. The role of higher order
complexes beyond receptor dimers is of special relevance for
HER2. Activation of HER2 in the context of heterodimers of
HER2 and HER3 results in tyrosine phosphorylation of both
receptors. Given the kinase deficient nature of HER3, this
observed activation of HER2 has been ascribed to trans
phosphorylation in the context of higher order association
states for the ligand-bound heterodimers [39]. However, the
recent model for activation, discussed below, allows for a
simpler model of intramolecular phosphorylation of activated
HER2 as far as only the dominant tyrosine phosphorylation of
the carboxyl-terminal tail is concerned [40]. The kinase-
deficient HER3, on the other hand, exhibits elevated self-
association behavior in the absence of ligand, but not only
does it fail to form stable ligand-induced dimers [41] but also
its ligand-independent self-association is destabilized by
ligand binding [11]. This suggests that a complex equilibrium
of pre-associated inactive receptor complexes, active dimers,
and monomers is likely to exist on the surface of cells.
The transmembrane span of HER2 has long been implicated
as a key contributing factor to self-association and activation
control. The self-association capacity of the transmembrane
spans correlates with the degree of conservation of GXXXG
motifs, present in two copies and various levels of
conservation in all four receptors [42]. Surprisingly, the well
known activating mutation of the transmembrane span
(V659E, Neu), which alters one of the GXXXG motifs,
destabilizes interactions and has been suggested to shift the
equilibrium of two alternative packing modes representing the
active and inactive state of the receptor [43]. The ‘Neu’
mutation may therefore not activate by enhancing
dimerization but by increasing the probability at which
transiently stable complexes, resulting from random collisions,
switch stochastically into an active state. Although this model
requires further confirmation, critical contributions of the
transmembrane span in signaling are also confirmed by the
fact that chimera of the ECDs of HER3 and the cytoplasmic
domains of HER2 are only functional when connected
through the stronger self-associating transmembrane span of
HER2 [11] but not with the corresponding segment of HER3
[41]. This is consistent with the observation that the
transmembrane span of HER3 exhibits the weakest self-
association [42]. This further indication for a need for
conformational changes within the receptor complexes also
underscores the importance of comparisons with the
evolutionary related IR/IGF1R system in which the covalent
nature of the receptor dimers clearly necessitates additional
allosteric control mechanisms.
Recent crystallographic studies have provided fascinating
insights as to what allosteric activation might mean at the
level of the final receiving module, namely the kinase domain.
With the exception of crystals obtained in the presence of the
type II (inactive state) kinase inhibitor lapatinib, the kinase
domain of EGFR assumes an active conformation in all other
available crystal structures. This is consistent with the
observation that EGFR, in contrast to IR and indeed most
protein kinases, does not require phosphorylation of its
activation loop for activation.
Instead, recent studies conducted by Kuriyan and colleagues
[38] show that EGFR kinase domains achieve allosteric
activation by assuming a dimeric packing mode that
resembles interactions observed in the CDK2/cyclin A
complex [40]. In this model, two kinase domains form an
activated complex through the interaction of the carboxyl-lobe
of one kinase domain with the amino-lobe of a second kinase
domain. This destabilizes an inhibitory wedge between
leucines in the activation loop and the adjacent αC helix in
the amino-lobe of the kinase domain. This inhibitory control is
also lost in the heterozygous mutations L834R and L858R,
found frequently in EGFR in lung cancers. The identified
interface between kinase domains also includes the carboxyl-
terminal ‘LVI’ motif in EGFR, HER3 and HER4 (‘VVI’ in
HER2), which was known to be required for the formation of
catalytically competent heterodimers of HER2 and HER3
[44]. Although HER3 lacks conservation of the interface on
the amino-terminal lobe, which is needed to receive an
activating signal, it fully conserves its carboxyl-terminal
interface, presumably enabling it to act as an allosteric
activator for HER2 or EGFR (Figure 1b). This provides an
explanation for the overall conservation of the catalytically
dead kinase domain of ERBB3. Interestingly, deletions of
portions of the carboxyl-terminal tail segment result in a
release of intrinsic inhibitory blocks. The carboxyl-terminal tail
is an intrinsic part of an alternative, symmetric dimer interface
between kinase domains [45]. This interaction may therefore
present an alternative inhibitory packing mode.
The available model for allosteric cross-activation provides a
clear mechanistic foundation. However, in order to better
understand how this model can be reconciled with the
observation that preformed dimers can exist in either active or
inactive states, we will need further structural information on
the components that link the ligand binding domains to the
kinase domains and on the interplay of those modules
throughout the activation process. How allosteric changes
may be passed on from the ECDs to the interior, once dimers
are formed, is not clear at this point. However, the model of
alternative transmembrane packing modes provides one
attractive option [43].
All of the models presented above attempt to explain the
basic signaling behavior of HER2 either based on an
individual receptor or complexes between RTKs. However,
although activation results in the recruitment of various
adapter proteins to the receptors, it is important to realize that
HER2 is not free of cytoplasmic associations in its
nonactivated state. Specifically, HER2 is stabilized by the
Available online http://breast-cancer-research.com/content/9/1/202
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HER2, Hsp90 also interferes with the heterodimerization of
HER2 and HER3 [46], and the conserved recognition motif
for Hsp90 [47] overlaps with the recently discovered
allosteric activation interface in the amino-terminal lobe of the
HER2 kinase domain. This poses interesting and as yet
unresolved questions with regard to the order of events in
HER2 activation.
In addition, the juxtamembrane region of EGFR associates
with calmodulin in a manner that is regulated through
threonine phosphorylation (Thr654) by protein kinase C [48].
Such an association with calmodulin has also been
demonstrated for HER2 [49]. This would dramatically change
the charge composition of the juxtamembrane section, which
has been proposed to contribute to activation control [50].
Calmodulin binding would also alter the flexibility of the
juxtamembrane linker region. Such an addition of rigidity may
be of relevance in the context of the proposed allosteric
activation scheme for RTK kinase domains and the mode of
transmission of conformational changes from the exterior to
the interior.
However, how these additional control mechanisms act in a
concerted manner under normal ligand-controlled conditions,
and how their alterations may factor into the loss of control in
over-expressing cancers is not clear at this point.
Conclusion
Structural information on the mode of interaction between
EGFR-type RTKs has provided a wealth of information on a
mechanistic level and satisfactory explanations for the mode
of action of some of the second-generation monoclonal
antibodies. Binding of cetuximab (Erbitux, ImClone Systems,
New York, NY, USA) to domain III of EGFR interferes with
ligand binding and the ability of the receptor to adopt an
extended conformation [26], and pertuzumab (2C4,
Omnitarg, Genentech, San Francisco, CA, USA) targets the
dimerization motif in domain II of ERBB2 [51], thereby
preventing the formation of signaling competent
heterodimers. Additional antibody-based therapeutics are
currently under investigation but the direct correlation
between now established mechanistic features of RTK
signaling and antibody activity is not always as clear. This
remains to be the case for Herceptin (trastuzumab), although
one of its properties - the interference with the generation of
the hyperactive cleavage product of HER2 (p95HER2) [52] -
can be reconciled nicely with the available co-crystal
structure of HER2 and Herceptin.
Combined structural and biochemical studies have also
shown that the established model of ligand-induced
dimerization correctly identifies an essential stage in receptor
control but is insufficient to provide a complete picture of the
control mechanism within this complex signal transmission
device represented by EGFR-type receptors. On the one
hand, we currently lack sufficient mechanistic insights into the
coupling of external ligand binding events to kinase domain
activation, and receptor dimerization alone is clearly not
sufficient. On the other hand, we have in the intramolecular
tether a structurally very well defined control mechanism in
search of its proper place in the overall scheme of receptor
control. This complexity of receptor intrinsic control
mechanisms is superimposed on secondary layers of control
such as receptor associating factors such as Hsp90 or
calmodulin, and subcellular localization such as membrane
microdomain partitioning. A better understanding of these
different levels of control will certainly not only lead to better
targeted and mechanistically based drugs, but should also
provide insight into the mechanisms underlying emerging
resistance as well as mechanisms that lead to differences in
the ultimate outcome of signaling. The latter may ultimately
allow us not only to think of RTKs in general, and HER2 in
particular, as overactive receptors to be inhibited, but also
may teach us how to actively redirect the signaling of over-
expressed HER2 receptors into a proapoptotic direction,
given that apoptosis is part of the repertoire of signaling
outcomes for HER2.
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